Silence Therapeutics plc (SLN)
NASDAQ
Healthcare
Biotechnology
$9.09
▼ -7.81%
Market Cap
$429.4M
Sector
Healthcare
Industry
Biotechnology
Beta
1.38
52-Wk Range
4.19-11.06
CEO
Iain Gladstone Ross
Country
GB
Currency
USD
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) mole…
Open full interactive analysis & DCF →